2-[2-(2-Amino-6-hydroxy-purin-9-yl)-ethyl]-propane-1,3-diol

ID: ALA1540

Cas Number: 39809-25-1

PubChem CID: 135398748

Product Number: P125160, Order Now?

Max Phase: Approved

First Approval: 1996

Molecular Formula: C10H15N5O3

Molecular Weight: 253.26

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Penciclovir | BRL-39123 | NSC-759624

Synonyms from Alternative Forms(4): Penciclovir sodium | Sodium penciclovir | BRL-39123-D | Denavir

Trade Names(3): Denavir | Fenistil | Vectavir

Canonical SMILES:  Nc1nc(O)c2ncn(CCC(CO)CO)c2n1

Standard InChI:  InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)

Standard InChI Key:  JNTOCHDNEULJHD-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 18 19  0  0  0  0  0  0  0  0999 V2000
    3.0250   -5.4292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0208   -4.6042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3083   -5.8417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042   -4.3417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5958   -4.6042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8125   -5.6792    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3083   -4.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5958   -5.4250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2958   -5.0083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8042   -6.5042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8792   -5.8375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3083   -3.3667    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5125   -6.9208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2333   -6.5167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9625   -5.2833    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.6583   -6.5333    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.2417   -5.6917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9417   -6.9333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  1  1  0
  4  2  1  0
  5  8  1  0
  6  1  1  0
  7  2  1  0
  8  3  2  0
  9  6  1  0
 10  6  1  0
 11  8  1  0
 12  7  1  0
 13 10  1  0
 14 13  1  0
 15 17  1  0
 16 18  1  0
 17 14  1  0
 18 14  1  0
  4  9  2  0
  7  5  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA1540

   Penciclovir

2. Alternative Forms:

   

   ALA1540

   Sodium penciclovir

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: Yes

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: Yes

Calculated Properties

Molecular Weight: 253.26

Molecular Weight (Monoisotopic): 253.1175

AlogP: -0.90

#Rotatable Bonds: 5

Polar Surface Area: 130.31

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.59

CX Basic pKa: 0.94

CX LogP: -1.08

CX LogD: -1.08

Aromatic Rings: 2

Heavy Atoms: 18

QED Weighted: 0.54

Np Likeness Score: -0.33

References

1. Bisacchi G, Chao S, Bachard C, Daris J, Innaimo S, Jacobs G, Kocy O, Lapointe P, Martel A, Merchant Z, Slusarchyk W, Sundeen J, Young M, Colonno R, Zahler R.  (1997)  BMS-200475, a novel carbocyclic 2-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro,  7  (2): [10.1016/S0960-894X(96)00594-X]

2. Harnden MR, Jarvest RL, Bacon TH, Boyd MR..  (1987)  Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.,  30  (9): [PMID:3040998] [10.1021/jm00392a020]

3. Harnden MR, Jarvest RL, Boyd MR, Sutton D, Vere Hodge RA..  (1989)  Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.,  32  (8): [PMID:2754699] [10.1021/jm00128a012]

4. Kim D, Lee N, Im GJ, Kim Y, Chang K, Kim H, Cho Y, Choi W, Jung I, Kim KH.  (1996)  Synthesis and evaluation of amino acid ester prodrugs of penciclovir,  6  (15): [10.1016/0960-894X(96)00329-0]

5. Kumar R, Nath M, Tyrrell DL..  (2002)  Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus.,  45  (10): [PMID:11985471] [10.1021/jm010410d]

6. Ashton WT, Meurer LC, Cantone CL, Field AK, Hannah J, Karkas JD, Liou R, Patel GF, Perry HC, Wagner AF..  (1988)  Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.,  31  (12): [PMID:2848125] [10.1021/jm00120a010]

7. Lin Y, Zembower DE, Flavin MT, Schure RM, Anderson HM, Korba BE, Chen F.  (1997)  Robustaflavone, a naturally occurring biflavanoid, is a potent non-nucleoside inhibitor of hepatitis B virus replication in vitro,  7  (17): [10.1016/S0960-894X(97)00422-8]

8. Legraverend M, Boumchita H, Zerial A, Huel C, Lemaitre M, Bisagni E..  (1990)  Synthesis of new (+-)-3,5-dihydroxypentyl nucleoside analogues from 1-amino-5-(benzyloxy)pentan-3-ol and their antiviral evaluation.,  33  (9): [PMID:2391689] [10.1021/jm00171a022]

9. Choi Y, Li L, Grill S, Gullen E, Lee CS, Gumina G, Tsujii E, Cheng YC, Chu CK..  (2000)  Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.,  43  (13): [PMID:10891113] [10.1021/jm990543n]

10. Onishi T, Mukai C, Nakagawa R, Sekiyama T, Aoki M, Suzuki K, Nakazawa H, Ono N, Ohmura Y, Iwayama S, Okunishi M, Tsuji T..  (2000)  Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.,  43  (2): [PMID:10649983] [10.1021/jm9904194]

11. Kumar R, Tyrrell DL..  (2001)  Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.,  11  (22): [PMID:11677126] [10.1016/s0960-894x(01)00589-3]

12. Kim DK, Lee N, Kim YW, Chang K, Kim JS, Im GJ, Choi WS, Jung I, Kim TS, Hwang YY, Min DS, Um KA, Cho YB, Kim KH..  (1998)  Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.,  41  (18): [PMID:9719596] [10.1021/jm980138g]

13. Kumar R, Sharma N, Nath M, Saffran HA, Tyrrell DL..  (2001)  Synthesis and antiviral activity of novel acyclic nucleoside analogues of 5-(1-azido-2-haloethyl)uracils.,  44  (24): [PMID:11708924] [10.1021/jm010227k]

14. Rahim SG, Trivedi N, Bogunovic-Batchelor MV, Hardy GW, Mills G, Selway JW, Snowden W, Littler E, Coe PL, Basnak I, Whale RF, Walker RT..  (1996)  Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.,  39  (3): [PMID:8576922] [10.1021/jm950029r]

15. Chitneni SK, Deroose CM, Balzarini J, Gijsbers R, Celen SJ, de Groot TJ, Debyser Z, Mortelmans L, Verbruggen AM, Bormans GM..  (2007)  Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography.,  50  (5): [PMID:17298046] [10.1021/jm060964m]

16. Focher F, Lossani A, Verri A, Spadari S, Maioli A, Gambino JJ, Wright GE, Eberle R, Black DH, Medveczky P, Medveczky M, Shugar D..  (2007)  Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.,  51  (6): [PMID:17438061] [10.1128/aac.01284-06]

17. Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H..  (2009)  Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.,  17  (2): [PMID:19112024] [10.1016/j.bmc.2008.11.075]

18. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A..  (2009)  Physicochemical determinants of human renal clearance.,  52  (15): [PMID:19445515] [10.1021/jm900403j]

19. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD..  (2010)  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,  53  (3): [PMID:20070106] [10.1021/jm901371v]

20. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]

21. Sáez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De León Castrejón T, Bomgaars L, Roberts M, Abrams B, Zhou W, Looby M, Kaiser G, Hamed K..  (2009)  Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.,  53  (5): [PMID:19273678] [10.1128/aac.01054-08]

22. Crosby IT, Bourke DG, Jones ED, Jeynes TP, Cox S, Coates JA, Robertson AD..  (2011)  Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV).,  21  (6): [PMID:21333535] [10.1016/j.bmcl.2011.01.109]

23. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

24. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF..  (2004)  Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.,  1  (4): [PMID:16472241] [10.2174/1570163043334794]

25. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

26. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

27. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

28. Mancha SR, Regnery CM, Dahlke JR, Miller KA, Blake DJ..  (2013)  Antiviral activity of (+)-sattabacin against varicella zoster.,  23  (2): [PMID:23219702] [10.1016/j.bmcl.2012.11.017]

29. PubChem BioAssay data set, 

30. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

31. Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning,  [10.6019/CHEMBL3392926]

32. Cheng Y, Vapurcuyan A, Shahidullah M, Aleksunes LM, Pelis RM..  (2012)  Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.,  40  (3): [PMID:22190696] [10.1124/dmd.111.042036]

33. PubChem BioAssay data set, 

34. Unpublished dataset, 

35. WHO Anatomical Therapeutic Chemical Classification, 

36. British National Formulary (72nd edition), 

37. DrugMatrix,  [10.6019/CHEMBL3885881]

38. DailyMed|setid=5c133dfe-3cb5-426b-ac30-daf814e12c47 | FAMCICLOVIR - famciclovir tablet, film coated|Golden State Medical Supply, Inc, 

39. Derudas M, Vanpouille C, Carta D, Zicari S, Andrei G, Snoeck R, Brancale A, Margolis L, Balzarini J, McGuigan C..  (2017)  Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.,  60  (18): [PMID:28829913] [10.1021/acs.jmedchem.7b01009]

40. Luo M, Groaz E, De Jonghe S, Snoeck R, Andrei G, Herdewijn P..  (2018)  Amidate Prodrugs of Cyclic 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity.,  9  (4): [PMID:29670705] [10.1021/acsmedchemlett.8b00079]

41. Unpublished dataset, 

42. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

43. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

44. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

45. Manevski N, King L, Pitt WR, Lecomte F, Toselli F..  (2019)  Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.,  62  (24): [PMID:31385704] [10.1021/acs.jmedchem.9b00875]

46. Mohammed AF, Andrei G, Hayallah AM, Abdel-Moty SG, Snoeck R, Simons C..  (2019)  Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.,  27  (6): [PMID:30738653] [10.1016/j.bmc.2019.02.005]

47. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

48. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

49. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

50. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

51. Gil C,Ginex T,Maestro I,Nozal V,Barrado-Gil L,Cuesta-Geijo MÁ,Urquiza J,Ramírez D,Alonso C,Campillo NE,Martinez A.  (2020)  COVID-19: Drug Targets and Potential Treatments.,  63  (21): [PMID:32511912] [10.1021/acs.jmedchem.0c00606]

52. Choudhry N,Zhao X,Xu D,Zanin M,Chen W,Yang Z,Chen J.  (2020)  Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).,  63  (22.0): [PMID:32845145] [10.1021/acs.jmedchem.0c00626]

53. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

54. Birkmann A, Bonsmann S, Kropeit D, Pfaff T, Rangaraju M, Sumner M, Timmler B, Zimmermann H, Buschmann H, Ruebsamen-Schaeff H..  (2022)  Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.,  65  (20.0): [PMID:36202389] [10.1021/acs.jmedchem.2c00668]

55. Shagufta, Ahmad I..  (2021)  The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.,  213  [PMID:33486200] [10.1016/j.ejmech.2021.113157]

56. Amin SA, Jha T..  (2020)  Fight against novel coronavirus: A perspective of medicinal chemists.,  201  [PMID:32563814] [10.1016/j.ejmech.2020.112559]

57. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(15):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• Drugs for Neglected Diseases Initiative (DNDi)
• DrugMatrix
• AstraZeneca Deposited Data
• Curated Drug Pharmacokinetic Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6